United States Liquid Biopsy Market reached US$ 305.4 Million in 2021
United States Liquid Biopsy Market is expected to reach US$ 803.8 Million by 2027. Liquid biopsy is the molecular examination of nucleic acids, subcellular structures, particularly exosomes, and, in the case of cancer, circulating tumor cells in bodily fluids. Liquid biopsy has been the subject of intense research over the last ten years to develop a less invasive and more precise individualized therapy. Furthermore, due to its sophisticated nature, which includes a short turnaround time and feasibility and the capacity to do early cancer screening, liquid biopsies are becoming more popular in the United States.
United States Liquid Biopsy Market Size is expected to expand at a CAGR of 17.50% during 2021-2027
The liquid biopsy methods are minimally invasive and cost-effective in the United States. As a result, they are a popular alternative for cancer diagnosis among Americans. Other essential driving factors influencing the US liquid biopsy market in the projected period include an increase in patient demand for non-invasive treatment procedures and the number of cancer patients. However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
How COVID-19 Affected United States Liquid Biopsy Industry
The coronavirus outbreak damaged the US biopsy diagnostics centers, hospitals, supply chains, and clinical trials. As a result, cancer diagnoses were being delayed since clinics had been closed since the start of the COVID-19 pandemic, and diagnosis and screening services were growing slower. In addition, cancer patients had numerous obstacles outside of the pandemic, including increased susceptibility to severe infection and disruptions in treatment or routine medical care. According to our estimates, the United States Liquid Biopsy Market reached US$ 305.4 Million in 2021 post recovery from the pandemic scenario.
Lung Cancer Accounts for The Dominant Market Share in The Forecast Period
The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer. Lung cancer is expected to have the largest market share during the projection period. According to the American Cancer Society, non-small-cell lung cancer, the most frequent kind of lung cancer in the United States, will be diagnosed in 235,760 persons in 2021. Lung cancer affects one in every 17 men and one in every 15 women at some point in their lives.
By Product, Assay Kits Holds the Largest Market Share
The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services. The kits and consumables are expected to have the most significant market share during the projection period. In the projection period, demand for kits and consumables will be driven by the ability to repeat sampling for liquid biopsy and their convenience and affordability.
Circulating Tumor Cells Maintains Their Dominance
The liquid biopsy market in the United States is classified into Circulating tumor cells (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs), and Other biomarkers based on the circulating biomarker (cell-free DNA, etc.). Circular tumor cells are expected to maintain their dominance throughout the predicted period. The market demand for Circulating tumor DNA is being driven by the rising frequency of cancer and the introduction of ctDNA-based liquid biopsy analysis, which can evaluate prognosis and tumor progression (ctDNA).
Other Segment Covered in Our Report Includes the Following
- Based on clinical application, the market has been segmented into monitoring, prognosis, theranostics, and screening.
- In addition, the market has been segmented into blood, urine, and others based on a sample.
- Finally, based on application, the market has been segmented into molecular health monitoring, therapy selection for other meta cancer, and therapy selection for MBS.
- The market has been segmented into hospitals and laboratories and government & academic research centers based on end-user.
Key Companies Insights
Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc, and Qiagen are among the important players profiled in our report. These market players in the United States contribute to market growth by diversifying their cancer diagnostics portfolios, resulting in increased demand for their biopsy test kits.
The publisher's latest report “United States Liquid Biopsy Market, Forecast By Cancer (Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer and Others), By Product (Kits & Consumables, Instruments and Services), Circulating Biomarkers (Circulating tumor cell (CTCs), Circulating tumor DNA (ctDNA), Extracellular vesicles (EVs) and Other biomarkers (cell free DNA,etc)), Clinical Application (Monitoring, Prognosis, Theranostics and Screening), Sample (Blood, Urine and Others), Application (Molecular Health Monitoring, Therapy Selection for Other Meta Cancer and Therapy Selection for MBS), End User (Hospitals and Laboratories and Government & Academic Research Centers), Companies (Thermo Fisher Scientific Inc, Roche Diagnostics, Bio-Rad Laboratories Inc, Biocept, Inc., Biocartis, Myriad Genetics, Inc., Exact Sciences (Genomic Health), NeoGenomics Laboratories, Quest Diagnostic Inc and Qiagen)” provides a detailed analysis of United States Liquid Biopsy Industry.
By Cancer, the Market has been segmented into 5 viewpoints
1. Lung Cancer
2. Breast Cancer
3. Colorectal Cancer
4. Prostate Cancer
5. Others
By Product the Market has been segmented into 3 viewpoints
1. Kits & Consumables
2. Instruments
3. Services
By Circulating Biomarkers, the market has been segmented into 4 viewpoints
1. Circulating tumor cell (CTCs)
2. Circulating tumor DNA (ctDNA)
3. Extracellular vesicles (EVs)
4. Other biomarkers (cell free DNA,etc)
By Clinical Application the market has been segmented into 4 viewpoints
1. Monitoring
2. Prognosis
3. Theranostics
4. Screening
By Sample the market has been segmented into 3 viewpoints
1. Blood
2. Urine
3. Others
By Application, the market has been segmented into 3 viewpoints
1. Molecular Health Monitoring
2. Therapy Selection for Other Meta Cancer
3. Therapy Selection for MBS
By End User, the market has been segmented from 2 viewpoints
1. Hospitals and Laboratories
2. Government & Academic Research Centers
Company Insights
- Overview
- Product Portfolio
- Financial Insight
Companies Covered
1. Thermo Fisher Scientific Inc
2. Roche Diagnostics
3. Bio-Rad Laboratories Inc
4. Biocept, Inc.
5. Biocartis
6. Myriad Genetics, Inc.
7. Exact Sciences (Genomic Health)
8. NeoGenomics Laboratories
9. Quest Diagnostic Inc
10. Qiagen
Table of Contents
Companies Mentioned
- Thermo Fisher Scientific Inc
- Roche Diagnostics
- Bio-Rad Laboratories Inc
- Biocept, Inc.
- Biocartis
- Myriad Genetics, Inc.
- eoGeno Exact Sciences (Genomic Health)
- Nmics Laboratories
- Quest Diagnostic Inc
- Qiagen
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 180 |
Published | September 2022 |
Forecast Period | 2021 - 2027 |
Estimated Market Value ( USD | $ 305.4 Million |
Forecasted Market Value ( USD | $ 803.8 Million |
Compound Annual Growth Rate | 17.5% |
Regions Covered | United States |
No. of Companies Mentioned | 10 |